France· FR:63945150
FOMEPIZOLE AP-HP 5 mg/mL, solution à diluer pour perfusion
A fomepizole product containing sulfate de fomépizole, registered in France by ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS - AP-HP. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Fomepizole is registered in 14 of 19 countries.
Countries holding a registration under ATC V03AB34 (fomepizole), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Fomepizole · ATC V03AB34
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- SULFATE DE FOMÉPIZOLE
- Manufacturer
- ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS - AP-HP
- Country
- France (FR)
- ATC code
- V03AB34
- ATC class
- Fomepizole
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009562023315 ampoule(s) en verre de 20 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for fomepizole.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fomepizole · interactions on record
4 records
- 4 severe
Most severe, free to view
- EthanolB05XX04severe
- EthanolV03AB16severe
- EthanolV03AZ01severe
- EthanolV07AB03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fomepizole in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsFomepizole SERB 5 mg/ml, concentraat voor oplossing voor infusieSERB S.A.
- United StatesfomepizoleAmerican Regent, Inc.
- United KingdomAntizol 1.5g/1.5ml solution for infusion vialsImported (United States)
- CanadaANTIZOLENDO OPERATIONS LTD.
- IcelandFOMEPIZOLE SERBSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- United Kingdom (Northern Ireland) · Fomepizole Waymade
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/20b0814f-8eab-465c-be8a-7d42ac3dc19a GET /v1/drugs/20b0814f-8eab-465c-be8a-7d42ac3dc19a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63945150",
"date_amm": "1999-05-06",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "SULFATE DE FOMÉPIZOLE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about fomepizole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.